BIOSINO BIO-TEC (08247) announced that at the Hefei Economic and Technological Development Zone's 2026 New Year Corporate Gathering held on February 4, 2026, its indirect non-wholly-owned subsidiary, Bio-Med Technology (Hefei) Co., Ltd., was awarded the honorary title of "2025 Hefei Economic and Technological Development Zone Technology Innovation Star Enterprise." This recognition was conferred by the Zone's Party Working Committee and Administrative Committee. The award authoritatively affirms the subsidiary's past scientific and technological achievements and highlights its future development potential.
Notably, the BioCyteX (Clinical) high-end flow cytometer, independently developed by Bio-Med Technology (Hefei), has officially received its medical device registration certificate. This product is the first domestically branded high-end flow cytometer in China to obtain such a registration. Its performance meets top-tier domestic standards and is comparable to international imported brands, marking a substantial breakthrough for domestic flow cytometry in high-end fields and aligning with the national "import substitution" initiative.
The product utilizes four precision semiconductor lasers working collaboratively to simultaneously excite 21 fluorescent dyes and acquire 24 key parameters. Its detection sensitivity, resolution, and stability have reached internationally leading levels, fulfilling core clinical needs such as highly complex immunophenotyping and minimal residual disease (MRD) monitoring. The successful certification of the BioCyteX flow cytometer signifies a critical breakthrough for domestic flow cytometry, moving from "catching up" to "running alongside" international competitors in areas like complex optical design and multi-color fluorescence analysis.
Since its establishment in the Hefei Economic and Technological Development Zone in 2022, Bio-Med Technology (Hefei) has leveraged the zone's high-quality innovation resources to accelerate its growth. It has achieved multiple breakthroughs in the research and development, and market promotion, of high-end flow cytometers and supporting reagents. The company's products have now obtained several national and international medical device certifications. Its business covers 31 provinces, municipalities, and autonomous regions across China and has expanded into overseas markets.
Receiving this honor is expected to enhance the Group's brand influence in research, development, and technological innovation. It also lays a solid foundation for the Group to further expand its market presence in the broader health industry. The Company stated it will continue to strongly support its subsidiaries' technological innovation and industrial development, actively expand high-quality businesses, enhance competitiveness, and create greater value for shareholders.